



Vaccines and Global Health: The Week in Review
22 June 2024 :: Issue 756
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



Protecting more children, against more diseases, faster than ever before: Gavi, the Vaccine Alliance unveils plans for next 5-year period

- Gavi's new Investment Opportunity outlines plans for the Vaccine Alliance to **protect 500 million children, saving over 8 million lives between 2026 and 2030.**
- At a Forum co-hosted by Gavi, the African Union and the French Republic, **Gavi announced it will need at least US\$ 9 billion in new donor funding for this work.** In response, the United States of America, France, Spain, the private sector and philanthropy pledged early support worth at least US\$ 2.4 billion towards this goal.
- The Forum also saw the **launch of the African Vaccine Manufacturing Accelerator (AVMA)**, an innovative financing mechanism which aims to foster regional vaccine production and vaccine sovereignty on the African continent, with twelve sovereign and philanthropic donors committing to invest approximately US\$ 1.2 billion.
- Governments and donors also committed to **championing investment in the production of vaccines against cholera on the African continent.**

Paris / Geneva, 21 June 2024 – On 20 June Gavi, the Vaccine Alliance (**Gavi**) co-hosted the **Global Forum for Vaccine Sovereignty and Innovation with the African Union and the French Republic**. At this event, opened by the Chair of the Board of Gavi, the President of the French Republic, and the Chairperson of the African Union Commission (AUC), Gavi called on donors to support its efforts to protect more children, against more diseases, faster than ever before as it published its Investment Opportunity for its next strategic period, 2026–2030. The Forum also marked the launch of the African Vaccine Manufacturing Accelerator (AVMA), which will be backed by approximately US\$ 1.2 billion in donor funding over the next 10 years.

Countries from around the world participated in this Global Forum, including the Heads of State or Government of Botswana, Germany, Ghana, Norway, Rwanda, and Senegal, as well as high-level representatives from governments (including more than 25 Ministers) and the European Commission, and leaders of partner organisations such as WHO, UNICEF, the Global Fund and Unitaid, as well from civil society, development banks, and the private sector...

Today's announced targets mean that while Gavi vaccinated one billion children between 2000 and 2020, it is aiming to reach the next billion children in half the time. This acceleration through 2030 is critical at a time when countries combat the increasing risks of climate change, fragility, and economic instability – and in the last push towards the Sustainable Development Goals. Fifty percent of the vaccines in Gavi's portfolio help combat the twin threats of climate change and antimicrobial resistance, expand investments in outbreak and pandemic preparedness and response, and key vaccine programmes. In Gavi's next five-year strategy, it will aim to reach at least 50 million children with four doses of the malaria vaccine, and 120 million girls – saving 1.5 million lives – with the HPV vaccine.

Achieving this historic milestone will require effort from all of Gavi's stakeholders, with donors being asked to provide new funding of US\$ 9 billion. These pledges will be supplemented by a suite of innovative finance instruments that will maximise the impact of donor funding. Meanwhile, **countries implementing Gavi programmes are expected to contribute a**

record amount – over 40% – of their own routine vaccine costs during the next strategic period. This is compared to 10% just fifteen years ago, reflective of the Vaccine Alliance's unique model of country-ownership and sustainability of immunisation programmes. At the same time, immunisation programmes are expected to generate at least US\$ 100 billion in economic benefits for Gavi-implementing countries.

With Gavi's replenishment process for 2026–2030 only just beginning, the event saw early pledges from the United States of America, France, Spain and private sector and philanthropic donors worth at least US\$ 2.4 billion (see below for details). Gavi will now commence an intense period of fundraising, with a view to hosting a final pledging event in the next 7 to 12 months.

The Forum also saw the official launch of the African Vaccine Manufacturing Accelerator (AVMA), an innovative finance mechanism designed to boost regional vaccine production capabilities in Africa and thus improve the continent's resilience in the face of pandemics and other health emergencies.

Designed by Gavi in close collaboration with the African Union and Africa CDC, AVMA will offer incentives to the region's vaccine producers that successfully hit critical regulatory and supply milestones, helping to offset high upfront investment costs. Twelve sovereign and philanthropic donors committed to provide approximately US\$ 1.2 billion to AVMA, including around US\$ 800 million from Team Europe partners...

[Full list of financial and other commitments by countries and organizations at title link above]

.....

[Joint Statement 'Together for a global and effective response to cholera'](#)

Posted on 20 June 2024

1/ As countries improve their water and sanitation infrastructure, we believe that vaccination is also an important and effective tool in the fight against cholera. **To respond to the current cholera crisis, it is critical that global supply of oral cholera vaccines (OCV) can respond to surges in demand. Increasing the quantity as well as improving the distribution of OCV is key for long-term prevention and management of cholera outbreaks, alongside key multisectoral measures** such as improving water, sanitation, and hygiene (WASH), ensuring access to health care services and effectively engaging communities and strengthening diagnostics, surveillance, and case management, as part of our common efforts to achieve Sustainable Development Goals on access to clean water and sanitation (SDG 6) and on good health and wellbeing (SDG 3).

2/ We commend the impact of Gavi, the Vaccine Alliance's work over the past decade, notably through market shaping and programmatic and financing support for expanding supply and deployment of the preventive use of cholera vaccines as well as the OCV emergency stockpile, managed by the International Coordinating Group (ICG) on Vaccine Provision to respond to outbreaks. Working with Alliance Partners and countries since 2013, Gavi's efforts have supported an eighteen-fold increase in supply and further stimulated a production increase of 30% in 2024 and far more in 2025 for cholera vaccines. The collaboration between Gavi, the World Health Organization (WHO), UNICEF and the Global Task Force on Cholera Control (GTFCC) has been instrumental in supporting country's demand for OCV as well as the effective implementation of cholera vaccination campaigns.

3/ **We further believe that investing in OCV production capacity in Africa is key to diversifying the market and improving rapid access in areas at risk for future cholera**

outbreaks. We commend that the African Vaccine Manufacturing Accelerator (AVMA) is designed to support the financing of regional production of vaccines against priority diseases, including cholera, in line with i) the GTFCC: a Global Roadmap to 2030 and ii) with our pandemic prevention, preparedness, and response (PPPR) priorities. We look forward to supporting this objective through appropriate channels.

Endorsed by :

- Government of Canada
- Government of France
- Government of Germany
- Government of Ireland
- Government of Italy
- Government of Japan
- Government of Spain
- Government of Sweden
- Government of the United States
- Government of Australia
- European Commission
- BMGF
- WHO
- GAVI

.....

WHO - Multi-country outbreak of cholera, External situation report #15 - 19 June 2024

Overview

From 1 January 2024 to 26 May 2024, a cumulative total of 194 897 cholera cases and 1932 deaths were reported from 24 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the Region of the Americas, the South-East Asia Region, and the European Region. No outbreaks were reported in the Western Pacific Region during this time.

The global stockpile of Oral Cholera Vaccines (OCV) was depleted until early March but exceeded the emergency target of 5 million doses in early June for the first time in 2024. As of 10 June 2024, the stockpile has 6.2 million doses. However, demand for the vaccine continues to outpace supply. Since January 2023, 92 million OCV doses were requested by 16 countries, nearly double the 49 million doses produced during this period.

WHO classified the global resurgence of cholera as a grade 3 emergency in January 2023, the highest internal level for emergencies in WHO. Based on the number of outbreaks and their geographic expansion, alongside the shortage of vaccines and other resources, **WHO continues to assess the risk at the global level as very high and the event remains classified as a grade 3 emergency.**

.....

.....

International Bio Funders Compact to Integrate Biosecurity into Life Science Research Funding

20 June, 2024, OSLO, Norway and WASHINGTON DC, USA - Today the Nuclear Threat Initiative (NTI), in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), **launched the**

international Bio Funders Compact at the 2024 Global Health Security Conference in Sydney, Australia.

The Compact incorporates biosecurity into the bioscience research funding process to safeguard life science research from accidental or intentional misuse. Joining NTI and CEPI as founding signatories are Sentinel Bio — a new philanthropic fund launching soon — and the Global Health Security Fund.

The world is experiencing a 21st century bioscience and biotechnology revolution driven by rapid technological advances and accelerated by artificial intelligence. These advances offer significant potential benefits for promoting human health and pandemic preparedness, fostering economic development, and guarding against climate change. However, the accelerating global development of life science research and biotechnology is also contributing to **growing risks of accidents or deliberate misuse.**

Life science funders and investors in government, philanthropy, and the private sector hold significant leverage at the beginning of the bioscience and biotechnology research and development lifecycle. However, **many funders do not conduct rigorous biosecurity reviews as part of their decision-making processes, and there are no agreed-upon best practices for doing so. The Bio Funders Compact will address this critical gap.**

"I am very pleased to have signed the Bio Funders Compact this week on behalf of CEPI. It demonstrates our commitment as a research funder to promote safe, secure, and responsible investments in research against epidemic and pandemic threats. I am proud that CEPI is one of the first signatories to this important effort that will strengthen our collective capacity to safeguard life-saving research," said Dr. Richard Hatchett, CEO of CEPI...

The Compact will improve global security by strengthening funding-based incentives for scientists and technologists to comply with biosecurity and biosafety best practices, reduce the likelihood that funders will support unduly risky research, and promote a research culture that prioritizes safety and security.

Signatories commit to:

- **Implement pre-funding biosecurity and biosafety reviews** as part of the decision-making processes within our organization.
- **Conduct post-funding assessments of adherence** to biosecurity and biosafety best practices among researchers that we fund.
- **Develop implementation plans to fulfill this pledge** while focusing on the mission and needs of our respective organizations.
- **Designate an individual or team to oversee biosecurity and biosafety** pre- and post-funding reviews as well as other activities that align with this pledge.
- **Share best practices** for biosecurity and biosafety risk assessment and risk reduction among bioscience and biotechnology funding communities...

.....
.....
.....

Polio – PHEIC

[Polio this week as of 19 June 2024 - GPEI](#)

Headlines

:: G7 Leaders reaffirm commitment to polio eradication: Convening at their annual heads of state summit this week in Italy, [the Leaders of the G7](#) "recommit to ending HIV, tuberculosis, and malaria, in particular by supporting the Global Fund to Fight AIDS, Tuberculosis and Malaria, as well as neglected tropical diseases and polio as public health threats by 2030, and countering climate change effects on infectious diseases, which are already seen globally, including in recent cholera and dengue outbreaks."

Summary of new polioviruses this week, cases and positive environmental isolates:

:: Afghanistan: one WPV1 case and 10 positive environmental samples
:: Pakistan: three WPV1-positive environmental samples
:: Chad: one cVDPV2-positive environmental sample
:: Côte d'Ivoire: one cVDPV2-positive environmental sample
:: Guinea: two cVDPV2-positive environmental samples
:: Nigeria: three cVDPV2 cases
:: Senegal: two cVDPV2-positive environmental samples
:: South Sudan: one cVDPV2 case and one cVDPV2-positive environmental sample
:: Zimbabwe: two cVDPV2-positive environmental samples

.....

[Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa](#)

Paris, June 20, 2024.

Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. **This agreement is designed to enable regional manufacturing of polio vaccines to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer of IPV on and for the African continent** and supports the Africa Centers for Disease Control and Prevention's ambition to have 60 percent of local vaccines produced in Africa by 2040.

Thomas Triomphe, Executive Vice President, Vaccines, Sanofi, said "For 40 years, Sanofi has supplied billions of polio vaccine doses globally, supporting the world getting close to polio eradication. But with the COVID-19 pandemic, many routine pediatric vaccination programs were halted or disrupted. Catching up will be key to preventing a rise in cases in many countries worldwide and this Sanofi partnership with Biovac is a step in that direction. Establishing this manufacturing partnership now, ahead of time, is key to enabling Biovac's manufacturing capabilities for future international tenders."...

Sanofi has been a critical partner of the Global Polio Eradication Initiative since 1988 and has **supplied the world and UNICEF with more than 1.5 billion doses of IPV through GAVI**, the Vaccine Alliance, which aims to vaccinate the populations of more than 70 of the poorest countries on the planet with the aim to eradicate polio.

Sanofi will continue to produce the bulk of IPV and Biovac, who will hold the marketing authorization, will be responsible for late-stage formulation, filling, packaging, and delivery of millions of IPV doses to UNICEF for GAVI countries in Africa...

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

[:: Organization Announcements](#)
[:: Journal Watch](#)
[:: Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 22 June 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

No new digest content identified.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 21 June 2024

Congo reinforces health emergency preparedness and response

:: 19 June 2024

WHO Africa releases groundbreaking guidance to boost fight against sickle cell disease

... The new WHO Africa guidance documents, entitled Guidance Framework for Sickle Cell Disease Management and Harmonized Guide for Sickle Cell Disease Management in Africa, provide countries with strategic guidance for policies, comprehensive care plans and advocacy efforts...

WHO Region of the Americas PAHO

:: 20 Jun 2024

Despite record dengue cases, Latin America and the Caribbean maintain a low fatality rate

Washington, DC, June 20, 2024 (PAHO) – Latin America and the Caribbean has reported 9.3 million cases of dengue so far this year, twice the number of cases reported in all of 2023. However, according to the latest epidemiological update issued this week by the Pan American Health Organization (PAHO), the fatality rate remains below...

:: 18 Jun 2024

PAHO Director calls for action to reduce maternal mortality

Washington, DC, June 18, 2024 (PAHO) - The Director of the Pan American Health Organization (PAHO), Doctor Jarbas Barbosa, issued an urgent call to action to reduce maternal mortality in the Americas. In 2020, Latin America and the Caribbean experienced one maternal death every hour, reversing two decades of progress in maternal health indicators...

WHO South-East Asia Region SEARO

:: Battling Viral Hepatitis in Rohingya Camps amid mounting risk and resource crunch

19 June 2024 *News release*

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

Multi-country outbreak of cholera, External situation report #15 - 19 June 2024

Sudan conflict and refugee crisis, Multi-country External Situation Report #1 - 18 June 2024

Overview

This **situation report is the first WHO report summarizing the multi-country health situation and WHO response across the regional emergency caused by the conflict in Sudan**. Since the start of the conflict in April 2023, 10 million have been displaced internally—the largest number in the world—and 2 million into neighbouring countries including Chad, South Sudan, Egypt, and the Central African Republic. There is frequent re-displacement as lines of control continue to shift between the parties involved in the conflict.

In addition to direct health effects of the conflict such as trauma, there has been **extensive damage and disruption to the health system in Sudan, with millions in the country lacking access to healthcare, further exacerbating the already fragile health of many already vulnerable people**.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

14 June 2024 | Avian Influenza A(H5N2) - Mexico

14 June 2024 | Mpox - Democratic Republic of the Congo

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 24, pp. 327–338 21 June 2024

PDF: <https://iris.who.int/bitstream/handle/10665/377725/WER9925-eng-fre.pdf>

:: Technical advisory group on biosafety: annual meeting summary

:: Western equine encephalitis: geographical patterns and range expansion of an emerging arbovirus disease in the Americas

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

20 June 2024

Risk communication and community engagement readiness and response toolkit: dengue fever

20 June 2024

[WHO Inspection report of the variola virus repository at CDC, 2-6 May 2022](#)

19 June 2024

[Building health system resilience to public health challenges: guidance for implementation in countries](#)

18 June 2024

[Summary report on the WHO workshop on estimation of respiratory syncytial virus \(RSV\) disease burden...](#)

18 June 2024

[Report of the third, fourth and fifth meetings of the Technical Advisory Group on Malaria Elimination...](#)

18 June 2024

[Joint external evaluation of the International Health Regulations \(2005\) core capacities of Samoa -...](#)

17 June 2024

[Meeting of programme managers and the Regional Technical Advisory Group on dengue and other arboviruses...](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No meetings appear on calendar.

CDC/ACIP [U.S.] [to 22 June 2024]

<http://www.cdc.gov/media/index.html>

Latest News

Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

[June 26-28 - Draft Agenda](#)

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

June 20, 2024 / No. 24

[PDF of this issue](#)

- [Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak — Los Angeles County, June 2022–January 2023](#)
- [Findings from the First Year of a Federally Funded, Direct-to-Consumer HIV Self-Test Distribution Program — United States, March 2023–March 2024](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Faster access to clinical trial information in Europe](#)

Revised rules for Clinical Trials Information System (CTIS) become applicable
18 June 2024

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

[Communicable disease threats report, 15-21 June 2024, week 25](#)

20 Jun 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 15-21 June 2024, and includes updates on avian influenza, West Nile Virus infections, cholera, and mass gathering monitoring for the UEFA European Football Championship and Hajj.

.....
.....

Africa CDC [to 22 June 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

[Afreximbank and Africa CDC pledge \\$2 billion facility in support of Africa Health and Pharmaceutical Products Manufacturing](#)

20 June 2024

Paris, France: African Export-Import Bank (Afreximbank or the Bank) and the Africa Centers for Diseases Control and Prevention (Africa CDC) have renewed their partnership with a new cooperation agreement announced today on the sidelines of the Global Forum for Vaccine Sovereignty and Innovation in Paris, France. Through this collaboration, Afreximbank has committed a USD 2 billion facility to the "Africa Health Security Investment Plan" to support the health product manufacturing ambition of the continent. This initiative will focus on the African Pooled Procurement Mechanism (APPM) and the Platform for Harmonized African Health Products Manufacturing (PHAHM).

Articles

[Opinion: Here's what today's African vaccine accelerator launch means](#)

20 June 2024

The African Vaccine Manufacturing Accelerator launches today. It aims to invest at least \$1 billion over 10 years to meet the global need for vaccine supply against key diseases.

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 22 June 2024]

<http://en.nhc.gov.cn/>

News

[Receiving 404 Not Found response.]

National Medical Products Administration – PRC [to 22 June 2024]

<http://english.nmpa.gov.cn/>

News

[**NMPA holds meetings on vaccine regulatory QMS**](#)

2024-06-19

The National Medical Products Administration (NMPA) held meetings on the construction of the vaccine regulatory quality management system (QMS) in Nanjing, Jiangsu province, and Urumqi, Xinjiang Uygur autonomous region, on May 16 and May 30, respectively, in a bid to enhance the construction of the QMS and facilitate the cohesion and coordination of the QMS in the vaccine regulatory system.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-06-21 / No. 25

[View PDF of this issue](#)

- [Outbreak Reports: A Retrospective Investigation of a Case of Dual Infection by Avian-Origin Influenza A \(H10N5\) and Seasonal Influenza A \(H3N2\) Viruses — Anhui Province, China, December 2023–January 2024](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, April 2024](#)

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 22 June 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 22 June 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 22 June 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 22 June 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 22 June 2024]

<http://cepi.net/>

Latest News

[International Bio Funders Compact to Integrate Biosecurity into Life Science Research Funding](#)

CEPI 19th June 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 22 June 2024]

<https://cioms.ch/>

News; Publications; Events

[Glossary of ICH terms and definitions](#)

Version 6, 3 June 2024 -- This glossary combines the terms and definitions included in the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). It was compiled by CIOMS from the publicly available guidelines found on the ICH website. The guidelines themselves are owned by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)...

Year of publication: 2024

Number of pages: 218

SKU: 20016

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 22 June 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 22 June 2024]

<https://dukeghic.org/>

News

[Implementing AMR Surveillance Sustainably in Africa: Insights and Lessons from Ghana, Kenya, and Uganda](#)

Blog, Case Studies

18 June 2024

EDCTP [to 22 June 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

Website not responding at inquiry.

Emory Vaccine Center [to 22 June 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 22 June 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 22 June 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[Preparation for hospital surge capacity in disasters and emergencies](#)

Added June 16, 2024

[Screening asylum seekers for tuberculosis on entry to Germany](#)

Added June 15, 2024

Water-related impacts of climate change on agriculture and public health on Pakistan

Added June 14, 2024

Fondation Merieux [to 22 June 2024]

<http://www.fondation-merieux.org/>

News, Events

Événement co-organisé par la Fondation Mérieux

2ème édition du cours avancé sur l'épidémiologie dans les situations d'urgence complexes

15 - 19 juillet 2024 - Centre des Pensières, Veyrier-du-Lac (France)

Gavi [to 22 June 2024]

<https://www.gavi.org/>

Press Releases

21 June 2024

Protecting more children, against more diseases, faster than ever before: Gavi, the Vaccine Alliance unveils plans for next 5-year period

GE2P2 Global Foundation [to 22 June 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – June 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 17 June 2024 – Issue 19](#)

GHIT Fund [to 22 June 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 22 June 2024]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 22 June 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 22 June 2024]

<http://www.hilleman-labs.org/>

News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 22 June 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 22 June 2024]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 22 June 2024]

<https://www.iavi.org/>

News, Features

[Don't miss out on the 7th Global Forum on TB Vaccines this October](#)

June 18, 2024

IAVI is honored to be co-organizing the 7th Global Forum on TB Vaccines at a time of heightened attention to TB vaccine development and implementation. Rio de Janeiro, Brazil, from October 8-10, 2024.

INSERM [to 22 June 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 22 June 2024]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

[Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.](#)

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Varying deadlines depending on regulatory authority

ICRC [to 22 June 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 22 June 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 22 June 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified....

ISC / International Science Council [to 22 June 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 22 June 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 22 June 2024]

<http://www.ivi.int/>

IVI News & Announcements

[IVI welcomes President Macron's announcement of France's membership to IVI](#)

June 21, 2024

[IVI and Pasteur Network sign landmark MoU to enhance global health initiatives](#)

June 17, 2024

[IVI and ANRS Emerging infectious diseases \(ANRS MIE\) sign an agreement to collaborate for improved access to vaccines](#)

June 17, 2024

Johns Hopkins Center for Health Security [to 22 June 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 22 June 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Gaza-Israel war

[MSF-supported health facilities across Gaza face critical shortage of medica...](#)

Project Update 21 Jun 2024

Gaza-Israel war

[Without a ceasefire, healing mental trauma in Gaza is impossible](#)

Voices from the Field 20 Jun 2024

Tajikistan

[A timeline of tuberculosis treatment success in Tajikistan](#)

Project Update 19 Jun 2024

South Sudan

[War in Sudan exacerbates humanitarian needs in neighbouring South Sudan](#)

Press Release 18 Jun 2024

National Academy of Medicine - USA [to 22 June 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 22 June 2024]

<https://www.nationalacademies.org/newsroom?>

News

[Register for June 26 State of the Science Address](#)

Issues to be discussed include:

- U.S. global competitiveness in science and technology
- Alignment of U.S. research efforts with critical national priorities as public and private R&D funding shifts

- STEMM education to adequately prepare the next generation of leaders
- Public trust in science in an era of misinformation and disinformation

National Vaccine Program Office - U.S. HHS [to 22 June 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 22 June 2024]

<http://www.nih.gov/>

New Releases

No new digest content identified.

PATH [to 22 June 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 22 June 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 22 June 2024]

<http://www.unaids.org/en>

News, Stories, Updates

Press statement

[UNAIDS applauds Namibian High Court's decision to declare unconstitutional the law that had criminalised same-sex relationships](#)

GENEVA, 21 JUNE 2024

UNICEF [to 22 June 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 21 June 2024

[Immediate action required to prevent malnutrition crisis among children in Zambia - UNICEF](#)

LUSAKA, Zambia, 21 June 2024 – Almost 52,000 children under the age of five in the 84 drought-affected districts in Zambia are expected to fall into severe wasting – the deadliest form of malnutrition – within the next 12 months if urgent preventive measures are not put into place. Another 276,000 children under age five will have moderate wasting...

Unitaid [to 22 June 2024]

<https://unitaid.org/>

Featured News

21 June 2024

[Unitaid applauds France's steadfast commitment to sustainable global health interventions](#)

21 June 2024

[Unitaid calls for accelerated global access to long-acting HIV prevention drug lenacapavir after positive trial results](#)

19 June 2024

[Unitaid Executive Board sets vision for the future with approval of five new areas for intervention at 44th session](#)

...The five new investment areas will strengthen Unitaid's already robust investment pipeline in low- and middle-income countries by advancing core work in women's and children's health, regional manufacturing, health system strengthening and pandemic preparedness and response. Specifically, the interventions will:

- Improve access to care for moderate and severe anemia in pregnant and nursing women; children; and people who have been affected by malaria.
- Enhance risk detection and management of pre-eclampsia, a potentially fatal complication in pregnancy.
- Advance innovations in sustainable oxygen production and supply.
- Promote people-centered care through integrated diagnostic tools and delivery, and expanding access to self-testing for cervical cancer, HIV and tuberculosis.
- Support regional manufacturing of priority health products for equitable access and health security.

19 June 2024

[Unitaid to support African production of medicines and tools for postpartum hemorrhage, malaria and HIV with new call for proposals](#)

Vaccine Equity Cooperative [nee Initiative] [to 22 June 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 22 June 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 22 June 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 22 June 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

June 2024: Vaccines and Infectious Diseases in the News

Published on Jun 12, 2024

Wellcome Trust [to 22 June 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 22 June 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

The Wistar Institute Receives \$10 Million Donation

Brings Lead gift to \$30 million – Largest Contribution in Wistar’s History

PHILADELPHIA — (June 18, 2024) — The Wistar Institute received a \$10 million donation from an anonymous donor who previously committed \$20 million to support Wistar’s new Center for Advanced Therapeutics. This now \$30 million gift to Wistar’s Bold Science//Global Impact Campaign is the largest in the Institute’s history and enables Wistar to fund the design and construction of its new Center for Advanced Therapeutics, a cornerstone of the Institute’s strategic plan...

World Bank [to 22 June 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 22 June 2024]

<https://www.wfpha.org/>

Blog, Event

No new digest content identified.

World Medical Association [WMA] [to 22 June 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

Public Consultation on a Draft Revised Version of the Declaration of Helsinki

WMA Issued 03 June 2024

Email completed document **no later than 24 June 2024, 5pm Central Time (UTC-6)**

The workgroup’s proposed edits to date are now available for public comment. To submit your organization’s or your individual feedback, download the phase 2 public comment document and populate your comments in the row that corresponds to the DoH paragraph under review. If you wish to offer specific edits for consideration, indicate proposed new language with bold yellow highlighted language. Indicate any proposed deletions with a yellow highlighted strikethrough language. Please do not use Track Changes. Please ensure all comments are properly attributed by including your name, title and organisation. Email the completed document to doh@wma.net no later than 24 June 2024, 5pm Central

Time (UTC-6). Since this is the final comment period, submissions received after June 24 will not be considered.

World Organisation for Animal Health [OIE] [to 22 June 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 22 June 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 22 June 2024]

<https://www.bio.org/press-releases>

Press Releases

[BIO Applauds Introduction of Bipartisan Legislation to Reauthorize Program That Encourages Rare Pediatric Disease Research](#)

June 20, 2024

DCVMN – Developing Country Vaccine Manufacturers Network [to 22 June 2024]

<http://www.dcvmn.org/>

News; Upcoming events

[ANNUAL GENERAL MEETING 2024](#)

October 16 - 18, 2024 São Paulo, Brazil

ICBA – International Council of Biotechnology Associations [to 22 June 2024]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 22 June 2024]

<https://ifpma.org/>

News, Statements [Selected]

Press release 20 Jun 2024

[Pharmaceutical industry welcomes the launch of Gavi's new investment round and AVMA](#)

On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.

External study 21 Jun 2024

[The Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance](#)

Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Reliance (CIRS) has published a CIRS R&D Briefing that aims to better understand the provision of regulatory review documents and reports – what type of documents are requested, how often and how they are being used for risk-based decision-making (e.g. reliance).

International Alliance of Patients' Organizations – IAPO [to 22 June 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified

PhRMA [to 22 June 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

June 17, 2024

[Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate](#)

Bharat Biotech

Press Releases - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias -

[Efficacy study of the heterologous SOBERANA 02 and SOBERANA-Plus scheme](#)

Summary: A 24-week follow-up study of cohorts of vaccinated children aged 2-11 years and unvaccinated children aged 12-23 months demonstrated an effectiveness of 83.5% in preventing symptomatic disease caused by Omicron.

Author: BioCubaFarma Lancet Regional Health

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News

Jun 18, 2024

[**Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults**](#)

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases

[**U.S. FDA Approves CAPVAXIVE™ \(Pneumococcal 21-valent Conjugate Vaccine\) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults**](#)

June 17, 2024

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases - No new digest announcements identified

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases

June 21, 2024

[Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee](#)

June 20, 2024

[Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa](#)

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases

2024/06/18

[SINOVAC's Varicella Vaccine was Approved by China National Medical Products Administration \(NMPA\) for Use in Adolescents and Adults Aged 13 Years Old and Above](#)

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

ELSIcon Special Issue

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 6: E435-505 June 2024

<https://journalofethics.ama-assn.org/issue/antimicrobial-stewardship>

Antimicrobial Resistance

Microbes include bacteria, parasites, viruses, and fungi that constantly evolve. Antimicrobial resistance (AMR) happens when microbes change, becoming harder to treat in individual human and nonhuman animals and plants with antibiotic, antiparasitic, antiviral, and antifungal agents. Resistant pathogens are easily transmissible across human and nonhuman ecology, and this theme issue attends to ethical, clinical, and policy dimensions of this set of problems. National and international burden of AMR has been assessed in terms of infection incidence, deaths, hospital length of stay, and location-specific

costs of developing and applying specific pathogen-drug combinations to try to save lives and preserve food supplies. Routine and focused surveillance is key to understanding microbiological, individual, social, and ecological root causes, downstream effects, and sources of domestic and global inequity in AMR.

American Journal of Human Genetics

Jun 06, 2024 Volume 111 Issue 6 p997-1240

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

In recent years, polygenic risk scores (PRSs) have evolved from a statistical metric into a tool poised for introduction into clinical use. Yet, for all the promise presented by PRSs, researchers from multiple fields have highlighted several areas of concern that need to be considered before PRSs are fully integrated into standard of care. Chief among these are scientific and ethical matters related to the differential performance of PRSs across groups of humans. In this issue, Lewis et al. discuss how the eMERGE Network approached these challenges in a clinical trial that returned PRSs for ten conditions to over 25,000 US-based participants.

American Journal of Infection Control

June 2024 Volume 52 Issue 6 p625-744

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

June 2024 Volume 66 Issue 6 p927-1106

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

July 2024 114(7)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 6 (Jun 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/4/tpmd.110.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

Volume 331 June 2024

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 330 May 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/330/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 22 June 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 22 June 2024)

[Well-being approaches targeted to improve child and youth health post-COVID-19 pandemic: a scoping review](#)

Our previous work synthesized published studies on well-being interventions during COVID-19. As we move into a post-COVID-19 pandemic period there is a need to comprehensively review published strategies, appr...

Authors: Stephana Julia Moss, Cynthia Sriskandarajah, Rebecca Brundin-Mather, Michal S. Cherak, Sara J. Mizen, Maia Stelfox, Donna Halperin, Scott Halperin, Sofia B. Ahmed, Diane L. Lorenzetti, Stacie Smith, Micaela Harley, Perri R. Tutelman, Kathryn A. Birnie, Melanie C. Anglin, Henry T. Stelfox...

Citation: BMC Health Services Research 2024 24:758

Content type: Research Published on: 21 June 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 22 June 2024)

[A designathon to co-create HPV screening and vaccination approaches for mothers and daughters in Nigeria: findings from a community-led participatory event](#)

Oncogenic types of human Papillomavirus (HPV) infection cause substantial morbidity and mortality in Nigeria. Nigeria has low cervical cancer screening and vaccination rates, suggesting the need for community ...

Authors: Eneyi E Kpokiri, Agatha E Wapmuk, Chisom Obiezu-Umeh, Ucheoma Nwaozuru, Titilola Gbaja-Biamila, Ifeoma Obionu, Ekenechukwu Kokelu, Jennifer Smith, Benedict N Azuogu, Kayode Ajenifuja, Abdulhammed O Babatunde, Oliver Ezechi, Joseph D Tucker and Juliet Iwelunmor

Citation: BMC Infectious Diseases 2024 24:606

Content type: Research Published on: 20 June 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 22 June 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 22 June 2024)
[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 22 June 2024)
[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 22 June 2024)

[Unpacking the impact of COVID-19 on child immunization: evidence from Ghana](#)

With the onset of the COVID-19 pandemic, governments implemented social distancing regulations to limit the spread of the disease. Some health experts warned that these measures could negatively affect access ...

Authors: Kathrin Durizzo, Koku Awoonor-Williams, Kenneth Harttgen and Isabel Günther

Citation: BMC Public Health 2024 24:1652

Content type: Research Published on: 20 June 2024

[Attitudes toward an HPV vaccine for condyloma acuminata and willingness to undergo vaccination among STD clinic attendees in China: Focus on STI prevention with HPV vaccine](#)

Condyloma acuminata (CA) is a common, and recurrent sexually transmitted disease (STD) that greatly contributes to direct health care costs and has a substantial psychosocial impact. Human papillomavirus (HPV)...

Authors: Anqi-Liu, Jiali-Quan, Lingxian-Qiu, Yue-Huang, Wujian-Ke, Huachun-Zou, Ting-Wu and Xuqi-Ren

Citation: BMC Public Health 2024 24:1610

Content type: Research Published on: 17 June 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 22 June 2024)
[No new digest content identified]

BMJ Evidence-Based Medicine

June 2024 - Volume 29 - 3

<https://ebm.bmj.com/content/29/3>

[Reviewed earlier]

BMJ Global Health

May 2024 - Volume 9 - Suppl 2

https://gh.bmj.com/content/9/Suppl_2

Learning from success: the maternal and newborn health transition in exemplar countries

[New issue; No digest content identified]

Bulletin of the Atomic Scientists

May 2024

<https://thebulletin.org/magazine/2024-05/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(6); 2024 Jun 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/463492/>

[Reviewed earlier]

Cell

Jun 06, 2024 Volume 187 Issue 12 p2897-3162

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 50, Issue 4 July 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 6 Pages: 1177-1459 June 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Moving the Needle for Oncology Dose Optimization

[Reviewed earlier]

Clinical Therapeutics

May 2024 Volume 46 Issue 5 p381-440

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 3, June 2024

<https://journals.sagepub.com/toc/ctja/21/3>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 22 June 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 141 June 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/141/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 2 / April 2024

<https://www.liebertpub.com/toc/crispr/7/2>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 5 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2024 - Volume 37 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 22 June 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 2 Pages: 49-134 June 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 3, 2024

<https://www.tandfonline.com/toc/cdip20/34/3>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue S1 June 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

Introduction to Special Issue Open Access

Foresight and futures thinking for international development co-operation: Promises and pitfalls

Fraser Reilly-King, Colleen Duggan, Alex Wilner

First Published: 12 June 2024

Abstract

Motivation

Strategic foresight is gaining traction for anticipating changes in a volatile, uncertain, complex, and ambiguous (VUCA) world—one which will require different mindsets and approaches. Yet international development co-operation practitioners have been slow to adopt foresight.

Purpose

What promises and pitfalls should development practitioners consider in order to integrate strategic foresight into their work?

Methods and approach

We review the literature on strategic foresight applied to development. We draw on reflections from the articles included in this special issue. We incorporate the International Development Research Centre's experiences and early insights on the use of foresight for development.

Findings

Strategic foresight provides tools to anticipate long-term and potentially disruptive change. To apply the approach effectively, organizations need to understand the debates about foresight. But no one size fits all: organizations must identify where and how foresight can best be used; be clear on its purpose, use, and end-users; be sensitive to how foresight intersects with broader calls for decolonizing development and the future; and should adapt methods to different sociocultural contexts. Connecting foresight practitioners and international development actors to explore potential synergies between these two worlds offers opportunities to innovate.

Policy implications

Traditional, short-term strategic planning, and reactive responses to emerging crises, are increasingly ill-suited to a VUCA world. To be fit for the future, international development actors must consider adding proactive longer-term anticipatory planning—that accommodates more systematic understanding and appreciation of plausible futures—to reactive responses.

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 3 July 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/3>

Original Articles

Conflict, COVID-19, and crisis response: shifting from 'pivoting' to preparedness

Eleanor Gordon PhD

e12615

First Published: 14 December 2023

EMBO Reports

Volume 25 Issue 6 12 June 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 5—May 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 47 June 2024

<https://www.sciencedirect.com/journal/epidemics/vol/47/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 3 Pages: 1-39 May–June 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Children and human challenge studies Challenges for research with migrants

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 2, April 2024

<https://academic.oup.com/eurpub/issue/34/2>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2024 Volume 103, Number 3

<https://www.foreignaffairs.com/issues/2023/103/3>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 6 June 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/6>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 22 June 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 2 April 29, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 22 June 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 22 June 2024]

The paradox of growing technical capacities with low global governance: a review of Voluntary National Reviews' SDG health-related indicators

Authors: Ana Luisa Jorge Martins and Rômulo Paes-Sousa

Content type: Research 21 June 2024

Governance of the wildlife trade and the prevention of emerging zoonoses: a mixed methods network analysis of transnational organisations, silos, and power dynamics

Authors: Chloe Clifford Astbury, Anastassia Demeshko, Eduardo Gallo-Cajiao, Ryan McLeod, Mary Wiktorowicz, Cécile Aenishaenslin, Katherine Cullerton, Kirsten M. Lee, Arne Ruckert, A. M. Viens, Peter Tsasis and Tarra L. Penney

Health and Human Rights

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

SPECIAL SECTION – COMMEMORATING 30 YEARS

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 5, June 2024

<https://academic.oup.com/heapol/issue/39/5>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 22 June 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 9-10 / May 2024

<https://www.liebertpub.com/toc/hum/35/9-10>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

May 14, 2024 Volume 57 Issue 5 p927-1176

<https://www.cell.com/immunity/current>

Resource

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 22 June 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 22 June 2024]

[No new digest content identified]

International Health

Volume 16, Issue 3, May 2024

<https://academic.oup.com/inthealth/issue/16/3>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 5 (2024): May 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/112>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 3, June 2024

<https://academic.oup.com/ije/issue/53/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

June 18, 2024, Vol 331, No. 23, Pages 1977-2058

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

Health and the 2024 US Election

Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing

Dima M. Qato, PharmD, MPH, PhD; John A. Romley, PhD; Rebecca Myerson, MPH, PhD; et al.

JAMA. 2024;331(23):2043-2045. doi:10.1001/jama.2024.7348

This cross-sectional study uses data from retail pharmacies to examine shingles vaccine uptake among Medicare Part D beneficiaries following an IRA policy to eliminate cost sharing.

US Public Health Preparedness and Response to Highly Pathogenic Avian Influenza A(H5N1) Viruses

Noah Kojima, MD; Amelia Blumberg, MSPH; Rachel Radcliffe, DVM, MPH; et al.

JAMA. 2024;331(23):2045-2047. doi:10.1001/jama.2024.10116

US public health preparedness and response to highly pathogenic avian influenza A(H5N1) viruses are assessed in this survey study conducted by the CDC.

JAMA Health Forum

June 2024, Vol 5, No. 6

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

June 2024, Vol 178, No. 6, Pages 515-632

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIM Evidence Synthesis

April 2024 - Volume 22 - Issue 5

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Adolescent Health

June 2024 Volume 74 Issue 6 p1057-1270
<https://www.jahonline.org/current>
[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)
<https://www.jair.org/index.php/jair>
Contents
[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 3 June 2024
<https://link.springer.com/journal/10900/volumes-and-issues/49-3>
[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996
<https://www.cmro.in/index.php/jcmro/issue/view/75>
[Reviewed earlier]

Journal of Development Economics

Volume 169 June 2024
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/169/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024
<http://journals.sagepub.com/toc/jre/current>
[Reviewed earlier]

Journal of Epidemiology & Community Health

May 2024 - Volume 78 - 6
<https://jech.bmj.com/content/78/6>
[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 1 Pages: 1-235 March 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 2, May 2024

<https://muse.jhu.edu/issue/52595>

Table of Contents

[New issue; No digest content identified]

Journal of Immigrant and Minority Health

Volume 26, Issue 3 June 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-3>

[The Effect of a Quality Improvement Project on Improving Patients' Willingness to Receive an Influenza Vaccination in the Emergency Department](#)

Paola H. German, Mark Lazenby, Angela Jun

Original Paper Open access 04 January 2024 Pages: 474 - 481

[Ethnic Minority Participation in Clinical Trials from Latin America and the Caribbean: A Scoping Review](#)

Percy Herrera-Añazco, Jerry K. Benites-Meza, Vicente A. Benites-Zapata

Review Paper 31 January 2024 Pages: 604 - 622

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 229, Issue 5, 15 May 2024

<https://academic.oup.com/jid/issue/229/5>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 4 Pages: 3-2228 May 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

June 2024 - Volume 50 - 6

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 269 June 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/269/suppl/C>

Editorial

[COVID-19 Research Delays Disproportionately Affected Pediatrician-Scientists from Backgrounds Under-Represented in Medicine](#)

Adin Nelson, Janet Lam, Sallie R. Permar, Erika Abramson

Article 113865

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

May/June 2024 - Volume 30 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[Reviewed earlier]

Journal of the Royal Society – Interface

June 2024 Volume 21 Issue 215

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 4, May 2024

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 6 • June 2024

<http://jvi.asm.org/content/current>

Editor's Pick Virology Commentary 29 May 2024

[A community science approach to public health and public trust in science](#)

Christine Marizzi, et al.

<https://doi.org/10.1128/jvi.00825-24>

The world was not prepared to predict and effectively combat the COVID-19 pandemic. A key aspect for prediction and preparation is surveillance of virus families that have pandemic potential. While surveillance efforts, e.g., for avian influenza viruses, are established in specific regions, urban centers are often overlooked. This leaves a blind spot in an area of vulnerability. Zoonotic infections...

The Lancet

Jun 22, 2024 Volume 403 Number 10445 p2663-2754

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

The Lancet Child & Adolescent Health

July 2024 Volume 8 Number 7 p467-544

<https://www.thelancet.com/journals/lanchi/issue/current>

[New issue; No digest content identified]

Lancet Digital Health

Jul 2024 Volume 6 Number 7 e433-e535

<https://www.thelancet.com/journals/landig/issue/current>

Viewpoint

[Overcoming colonialism in pathogen genomics](#)

Senjuti Saha, Yogesh Hooda, Gathsaurie Neelika Malavige, Muhammad Imran Nisar

Summary

Historical legacies of colonialism affect the distribution and control of scientific knowledge today, including within the pathogen genomics field, which remains dominated by high-income countries (HICs). We discuss the imperatives for decolonising pathogen genomics, including the need for more equitable representation, collaboration, and capacity-strengthening, and the shared responsibilities that both low-income and middle-income countries (LMICs) and HICs have in this endeavour. By highlighting examples from LMICs, we illuminate the pathways and challenges that researchers in LMICs face in the bid to gain autonomy in this crucial domain. Recognising the inherent value of local expertise and resources, we argue for a more inclusive, globally collaborative approach to pathogen genomics. Such an approach not only fosters scientific growth and innovation, but also strengthens global health security by equipping all nations with the tools needed to respond to health crises.

Lancet Global Health

Jul 2024 Volume 12 Number 7 e1068-e1213

<https://www.thelancet.com/journals/langlo/issue/current>

Comment

The west Africa Ebola virus disease outbreak: 10 years on

Henry Kyobe Bosa, et al.

Comment

The surge of mpox in Africa: a call for action

Jean B Nachega, et al. for the Mpox Research Consortium

Articles

Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis

Fiona Silke, et al.

Background

Cost-effectiveness analyses have been conducted for many interventions for HIV/AIDS, malaria, syphilis, and tuberculosis, but they have not been conducted for all interventions that are currently recommended in all countries. To support national decision makers in the effective allocation of resources, we conducted a meta-regression analysis of published incremental cost-effectiveness ratios (ICERs) for interventions for these causes, and predicted ICERs for 14 recommended interventions for Global Fund-eligible countries.

Viewpoint

Decolonising global health: why the new Pandemic Agreement should have included the principle of subsidiarity

Thana C de Campos-Rudinsky, et al.

Lancet Infectious Diseases

May 2024 Volume 24 Number 5 p437-556, e268-e343

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jun 2024 Volume 9 Number 6 e345-e410

<https://www.thelancet.com/journals/lanpub/issue/current>

Editorial

Rethinking information ecosystems and infodemics

The Lancet Public Health

Health Policy

Beyond misinformation: developing a public health prevention framework for managing information ecosystems

Atsuyoshi Ishizumi, et al.

Viewpoint

Best practices for government agencies to publish data: lessons from COVID-19

Bastian Herre, et al.

Lancet Respiratory Medicine

May 2024 Volume 12 Number 5 p337-418, e31-e35

<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 5 May 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-5>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 4, May 2024

<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 2 Pages: 271-516 June 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

Perspective Open Access

[Integrated Devices: A New Regulatory Pathway to Promote Revolutionary Innovation](#)

TED CHO, VRUSHAB GOWDA, HENNING SCHULZRINNE, BRIAN J. MILLER

First published: 22 January 2024

<https://doi.org/10.1111/1468-0009.12692>

Abstract

Policy Points

:: Current medical device regulatory frameworks date back half a century and are ill suited for the next generation of medical devices that involve a significant software component.

:: Existing Food and Drug Administration efforts are insufficient because of a lack of statutory authority, whereas international examples offer lessons for improving and harmonizing domestic medical device regulatory policy.

:: A voluntary alternative pathway built upon two-stage review with individual component review followed by holistic review for integrated devices would provide regulators with new tools to address a changing medical device marketplace

Molecular Therapy

Jun 05, 2024 Volume 32 Issue 6 p1597-2036

<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 630 Issue 8017, 20 June 2024

<https://www.nature.com/nature/volumes/630/issues/8017>

Editorial 17 Jun 2024

[The Sustainable Development Goals: can they be made smarter?](#)

Accounting for factors such as artificial intelligence in a more ambitious set of goals has a lot of merit — as long as urgency is not lost on the existing ones.

Editorial 19 Jun 2024

Human neuroscience is entering a new era — it mustn't forget its human dimension

The field is taking a leap forward thanks to innovative technologies, such as artificial intelligence. Researchers must improve consent procedures and public involvement.

Extending the Sustainable Development Goals to 2050 — a road map

The world should redouble its efforts on the SDGs, not abandon them. Here's how to progress the United Nations' agenda towards 2050.

Francesco Fuso Nerini, Mariana Mazzucato, Jeffrey Sachs

Comment 17 Jun 2024

Nature Biotechnology

Volume 42 Issue 5, May 2024

<https://www.nature.com/nbt/volumes/42/issues/5>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 22 June 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 6, June 2024

<https://www.nature.com/ng/volumes/56/issues/6>

The Egypt Genome Project

The recently launched Egyptian Genome Project aims to sequence genomic variants of 100,000 apparently healthy Egyptian adults, with around 8,000 individuals suspected to have a genetic disease, as well as 200 ancient Egyptian mummies. The project will provide the first comprehensive genomic dataset from Egypt and North Africa.

Mohamed A. Elmonem, et al.

Comment 29 Apr 2024

Nature Human Behaviour

Volume 8 Issue 5, May 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/5>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 5, May 2024

<https://www.nature.com/nm/volumes/30/issues/5>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 6, June 2024

<https://www.nature.com/nrd/volumes/23/issues/6>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 6, June 2024

<https://www.nature.com/nrg/volumes/25/issues/6>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 5, May 2024

<https://www.nature.com/nri/volumes/24/issues/5>

[Reviewed earlier]

New England Journal of Medicine

Volume 390 No. 23 June 20, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

[Fundamentals of Medical Ethics: Ethics and Highly Innovative Research on Brain Diseases](#)

S. Hendriks and C. Grady

Despite exciting advances, conducting brain research and appropriately implementing interventions or insights derived from it raise both familiar and new ethical challenges.

NEJM Evidence

Volume 3 No. 6 June 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 22 June 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 6 June 2024

<https://publications.aap.org/pediatrics/issue/153/6>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 6 June 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-6>
[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 22 June 2024)
[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>
(Accessed 22 June 2024)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 22 June 2024)
[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>
(Accessed 22 June 2024)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>
(Accessed 22 June 2024)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>
[Accessed 22 June 2024]
[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 22 June 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

June 18, 2024 vol. 121 no. 25
<https://www.pnas.org/toc/pnas/121/25>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 5, May 2024

<https://academic.oup.com/pnasnexus/issue/3/5>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 183 June 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/183/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

June 2024 Volume 291 Issue 2024

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 230 Pages e1-e6, 1-232 (May 2024)

<https://www.sciencedirect.com/journal/public-health/vol/230/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 3, May/June 2024

<https://journals.sagepub.com/toc/phrg/139/3>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 7, June 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

Research Ethics

Volume 20 Issue 2, April 2024

<http://journals.sagepub.com/toc/reab/current>

Special collection: Research Integrity and Research Misconduct

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 22 June 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

19 Jun 2024

[Social medicine and the social sciences in Latin America: conceptual tensions for the transformation of public health in the 20th century](#)

Opinion and analysis | Spanish

Risk Analysis

Volume 44, Issue 5 Pages: 1007-1267 May 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 22 June 2024]

[Reviewed earlier]

Science

Volume 384| Issue 6702| 21 Jun 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 3 June 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-3>
[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 751|12 Jun 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 22 June 2024]

[No new digest content identified]

Social Science & Medicine

Volume 348 May 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/348/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 22 June 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 2 April 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 59 May–June 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/59/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 6 Pages: i-iv, 447-540 June 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 18 Pages 3751-3930 (11 July 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/18>

Selected Content

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 22 June 2024]

Open Access Article

Correlates of Zero-Dose Status among Children Aged 12–23 Months in the Luambo Health District, Democratic Republic of Congo: A Matched Case–Control Study

by Esperent Ntambue Malu, Alain Nzanzu Magazani, Jean Bosco Kasonga, Adèle Mudipanu, Michel Kabamba Nzaji, Daniel Katuashi Ishoso and Dalau Mukadi Nkamba

Vaccines 2024, 12(7), 700; <https://doi.org/10.3390/vaccines12070700> - 21 Jun 2024

Abstract

Background: “Zero-dose” (ZD) refers to a child who has not received any doses of the pentavalent (diphtheria–tetanus–pertussis–Haemophilus influenzae type b (Hib)–hepatitis B) vaccine. ZD children are vulnerable to vaccine-preventable diseases (VPDs). Luambo health district (HD) is one of 26 HDs in [...]

Open Access Commentary

Evolution and Contribution of a Global Partnership against Measles and Rubella, 2001–2023

by Peter Strebel, Mark Grabowsky, Edward Hoekstra, Andrea Gay and Stephen Cochi

Vaccines 2024, 12(6), 693; <https://doi.org/10.3390/vaccines12060693> - 20 Jun 2024

Abstract

This article describes the arc of global measles and rubella elimination since 2000 from the perspective of the founding partners of the Measles Initiative. The Measles Initiative was formed in 2001 as a partnership among the American Red Cross, the Centers for Disease [...] Read more.

Value in Health

June 2024 Volume 27 Issue 6 p687-820

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 177 May 2024

<https://www.sciencedirect.com/journal/world-development/vol/177/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 22 June 2024]

Open Letter

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration

[version 1; peer review: awaiting peer review]

E. Wangeci Kagucia, et al.

<https://orcid.org/0000-0001-7382-8675>

Abstract

The Kenya Multi Site Serosurveillance (KEMIS) collaboration set out to implement an integrated, nationally representative, population-based program of serological surveillance for past infection for a number of important infectious diseases in Kenya. The project started in December 2021 and built on a portfolio of SARS-CoV-2 research conducted in 2020 and 2021. In this profile paper, we describe the background of the KEMIS collaboration, its aim and objectives, the Health and Demographic Surveillance System sites that were involved in data collection, and the key activities undertaken. We also explain how we established governance and management of the KEMIS collaboration, and reflect on opportunities, challenges, lessons learned, and future directions.

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 22 June 2024]

[Filter: All articles]

Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study

Fabienne Krauer, Felix Guenther, Marina Treskova-Schwarzbach, Viktoria Schoenfeld, Mihaly Koltai, Mark Jit, David Hodgson, Udo Schneider, Ole Wichmann, Thomas Harder, Frank G. Sandmann, Stefan Flasche

medRxiv 2024.06.20.24309248; doi: <https://doi.org/10.1101/2024.06.20.24309248>

Investigating the relationship between the immune response and the severity of COVID-19: a large-cohort retrospective study

Riccardo Giuseppe Margiotto, Emanuela Sozio, Fabio Del Ben, Antonio Paolo Beltrami, Daniela Cesselli, Martina Fabris, Francesco Curcio, Carlo Tascini, Guido Sanguinetti

medRxiv 2024.06.20.24309246; doi: <https://doi.org/10.1101/2024.06.20.24309246>

Adverse sequelae of the COVID-19 pandemic on mental health care in seven low- and middle-income countries: MASC study

Charlotte Hanlon, Heidi Lempp, Atalay Alem, Azeb Asaminew Alemu, Ruben Alvarado, Olatunde Ayinde, Adekunle Adesola, Elaine Brohan, Thandi Davies, Wubalem Fekadu, Oye Gureje, Lucy Jalagania, Nino Makhashvili, Awoke Mihretu, Eleni Misganaw, Maria Milenova, Tamara Mujirishvili, Olha Myshakivska, Irina Pinchuk, Camila Solis-Araya, Katherine Sorsdahl, Gonzalo Soto-Brandt, Ezra Susser, Olga Toro-Devia, Nicole Votruba, Anuprabha Wickramasinghe, Shehan Williams, Graham Thornicroft

medRxiv 2024.06.18.24309132; doi: <https://doi.org/10.1101/2024.06.18.24309132>

The role of socio-economic determinants in SARS-CoV-2 health outcomes: systematic review of population-based studies

Jinane Ghattas, Tatjana T. Makovski, Stéphanie Monnier-Besnard, Lisa Cavillot, Monika Ambrožová, Barbora Vašinová, Rodrigo Feteira-Santos, Peter Bezzegh, Felipe Ponce Bollmann, James Cottam, Romana Haneef, Niko Speybroeck, Paulo Jorge Nogueira, Maria João Forjaz, Joël Coste, Laure Carcaillon-Bentata, Brecht Devleesschauwer

medRxiv 2024.06.18.24309062; doi: <https://doi.org/10.1101/2024.06.18.24309062>

Infection control strategies in essential industries: using COVID-19 in the food industry to model economic and public health trade-offs

Christopher Henry, Ece Bulut, Sarah I. Murphy, Claire Zoellner, Aaron Adalja, Diane Wetherington, Martin Wiedmann, Samuel Alcaine, Renata Ivanek

medRxiv 2024.06.18.24309041; doi: <https://doi.org/10.1101/2024.06.18.24309041>

Molecular epidemiology of recurrent zoonotic transmission of mpox virus in West Africa

Delia Doreen Djuicy, Ifeanyi F. Omah, Edyth Parker, Christopher H Tomkins-Tinch, James Richard Otieno, Moïse Henri Moumbeket Yifomnjou, Loique Landry Messanga Essengue, Akeemat Opeyemi Ayinla, Ayotunde E. Sijuwola, Muhammad I. Ahmed, Oludayo O. Ope-ewe, Olusola Akinola Ogunsanya, Alhaji Olono, Philomena Eromon, Martial Gides Wansi Yonga, Gael Dieudonné Essima, Ibrahim Pascal Touoyem, Landry Jules Mouliem Mouchili, Sara Irene Eyangoh, Linda Easo, Inès Mandah Emah Nguidjol, Steve Franck Metomb, Cornelius Chebo, Samuel Mbah Agwe, Hans Makembe Mossi, Chanceline Ndongo Bilounga, Alain Georges Mballa Etoundi, Olusola Akanbi, Abiodun Ekwuenu, Odianosen Ehiakhamen, Chimaobi Chukwu, Kabiru Suleiman, Afolabi Akinpelu, Adama Ahmad, Khadijah Isa Imam, Richard Ojede, Victor Oripemaye, Kenneth Ikeata, Sophiyah Adelakun, Babatunde Olajumoke, Áine O'Toole, Andrew Magee, Mark Zeller, Karthik Gangavarapu, Patrick Varilly, Daniel J Park, Gerald Mboowa, Sofonias Kifle Tessema, Yenew Kebede Tebeje, Onikepe Folarin, Anise Happi, Philippe Lemey, Marc A Suchard, Kristian G. Andersen, Pardis Sabeti, Andrew Rambaut, Chikwe Ihekweazu, Idriss Jide, Ifedayo Adetifa, Richard Njoum, Christian T Happi

medRxiv 2024.06.18.24309115; doi: <https://doi.org/10.1101/2024.06.18.24309115>

Genomic epidemiology uncovers the timing and origin of the emergence of mpox in humans

Edyth Parker, Ifeanyi F. Omah, Patrick Varilly, Andrew Magee, Akeemat Opeyemi Ayinla, Ayotunde E. Sijuwola, Muhammad I. Ahmed, Oludayo O. Ope-ewe, Olusola Akinola Ogunsanya, Alhaji Olono, Philomena Eromon, Christopher H Tomkins-Tinch, James Richard Otieno, Olusola Akanbi, Abiodun Ekwuenu, Odianosen Ehiakhamen, Chimaobi Chukwu, Kabiru Suleiman, Afolabi Akinpelu, Adama Ahmad, Khadijah Isa Imam, Richard Ojede, Victor Oripemaye, Kenneth Ikeata, Sophiyah Adelakun, Babatunde Olajumoke, Delia Doreen Djuicy, Loique Landry Messanga Essengue, Moïse Henri Moumbeket Yifomnjou, Mark Zeller, Karthik Gangavarapu, Áine O'Toole, Daniel J Park, Gerald Mboowa, Sofonias Kifle Tessema, Yenew Kebede Tebeje, Onikepe Folarin, Anise Happi, Philippe Lemey, Marc A Suchard, Kristian G. Andersen, Pardis Sabeti, Andrew Rambaut, Richard Njoum, Chikwe Ihekweazu, Idriss Jide, Ifedayo Adetifa, Christian T Happi

medRxiv 2024.06.18.24309104; doi: <https://doi.org/10.1101/2024.06.18.24309104>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-
No new digest content identified.]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 22 June 2024]

Selected Research

Study Protocol Open Access

REVISED-Exploring attitudes to research involving human subjects among Vietnamese university students: establishing a prospective longitudinal mixed-methods student cohort at the University of Medicine and Pharmacy at Ho Chi Minh City

[version 2; peer review: 2 approved with reservations]

Vy Pham -Tram, et al.

Abstract

Research capacity is increasing in low- and middle-income countries (LMICs), with progressive development in the range and complexity of studies being undertaken, often in collaboration with high-income country partners. Although senior local stakeholders are typically involved in ensuring that research is conducted according to accepted standards for ethical and scientific quality, to date there has been little exploration of the views of younger generations around the ethics of research involving human subjects.

We present our protocol to establish a longitudinal mixed-methods student cohort at the University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam, that is investigating students' views around the ethics of clinical and public-health oriented research. We use a synergistic approach involving initial deliberative engagement activities (e.g. science cafes, debates) to inform participants about complex concepts, prior to formal quantitative and qualitative methods (surveys, focus group discussions and in-depth interviews) that are designed to explore the students' views in detail. We focus in particular on dengue research, i.e. research that addresses a locally relevant disease with which the students are likely familiar, and probe their thoughts on such themes as appropriate remuneration for research participants, involvement of vulnerable groups, use of human challenge trials in LMICs etc.

A snapshot of the cohort and its activities after one year is also presented; among 429 active students, primarily from the Faculty of Medicine, the proportions of male and female students were similar, the majority were from southern or central Vietnam where dengue is endemic, and available data indicates the cohort to be representative of the expected spectrum of socioeconomic groups.

The cohort provides a unique resource to investigate the views of young people on medical ethics, an important but hitherto underrepresented group in such discussions. Feedback indicates a clear interest in contributing thoughts and ideas to the development of clinical research in Vietnam.

*

*

*

*

Think Tanks

Brookings [to 22 June 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 22 June 2024]

<https://www.cgdev.org/>

All Research [Selected]

CGD NOTES

Making an Organization for Health Technology Assessment: Lessons from India

Victoria Fan et al.

June 17, 2024

The implementation of evidence-based medicine (EBM) relies on organizations to identify, develop, and apply evidence-based practices. While healthcare professionals often engage with service providers like hospitals and insurers for EBM implementation, they may be less familiar with organizations fo...

Chatham House [to 22 June 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 22 June 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 22 June 2024]

<https://www.csis.org/>

Reports [Selected]

Investing in Science and Technology

This report highlights the serious challenge posed by China's rapid advancements in AI, QIS, and semiconductors, emphasizing the need for policymakers to act decisively to secure the United States' future in the global technology race.

Report by Sujai Shivakumar, Charles Wessner, and Thomas Howell — June 18, 2024

Kaiser Family Foundation [to 22 June 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified

McKinsey Global Institute [to 22 June 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 22 June 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 22 June 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]
No new digest content identified.

Rand [to 22 June 2024]
<https://www.rand.org/pubs.html>
Published Research [Selected]
Jun 17, 2024

[Applying an Equity Lens to Digital Content Transparency and Global AI Standards: An Analysis of NIST AI 100-4 and 100-5](#)

This paper provides public comment on two National Institute of Standards and Technology draft publications on digital content transparency and global artificial intelligence standards, addressing the notable demographic disparity in the drafts.

Urban Institute [to 22 June 2024]
<https://www.urban.org/publications>
[New Research Publications - Selected](#)

Research Report
[Advancing Vaccine Equity through Community-Based Organizations](#)
June 21, 2024

The Centers for Disease Control and Prevention launched the Partnering for Vaccine Equity (P4VE) program in 2021 to address racial and ethnic disparities in adult immunization rates, particularly for COVID-19 and influenza. The P4VE program allocated \$156 million to over 500 national, state, and community-based organizations (CBOs) to improve equitable access to vaccination in underserved communities by promoting vaccine confidence and addressing barriers to vaccination opportunities.

The Urban Institute (Urban) was one of several national intermediary entities responsible for recruiting, overseeing, and providing technical assistance to CBOs participating in the P4VE program. This report describes the experiences of Urban's 24 CBO awardees and the technical support the Urban team provided them to implement vaccine equity projects in the third year of the P4VE program...

World Economic Forum [to 22 June 2024]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

[Public Consultation on a Draft Revised Version of the Declaration of Helsinki](#)

WMA Issued 03 June 2024

Email completed document **no later than 24 June 2024, 5pm Central Time (UTC-6)**

The workgroup's proposed edits to date are now available for public comment. To submit your organization's or your individual feedback, download the phase 2 public comment document and populate your comments in the row that corresponds to the DoH paragraph under review. If you wish to offer specific edits for consideration, indicate proposed new language with bold yellow highlighted

language. Indicate any proposed deletions with a yellow highlighted strikethrough language. *Please do not use Track Changes.* Please ensure all comments are properly attributed by including your name, title and organisation. Email the completed document to doh@wma.net no later than 24 June 2024, 5pm Central Time (UTC-6). Since this is the final comment period, submissions received after June 24 will not be considered.

Consideration for Adoption: General Assembly Meeting Helsinki, Finland

The workgroup intends to recommend a final updated draft of the Declaration of Helsinki to the Medical Ethics Committee of the World Medical Association, and the document is intended to be considered by the Council and the General Assembly in Helsinki, Finland in October 2024.

National Institutes of Health (NIH) Office of Science Policy (OSP): Request for Information on Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning

A Notice by the National Institutes of Health on 05/22/2024 **Comments Close: 07/22/2024**

SUMMARY:

The National Institutes of Health (NIH) is proposing to develop and implement a new policy within its Intramural Research Program (IRP) to promote access to products stemming from taxpayer-funded inventions. NIH seeks input on this draft policy and accompanying draft license agreement language that incorporates patient access in the commercialization process for NIH-owned inventions.

Supplemental Information

...NIH is proposing a new policy within the NIH IRP (see Appendix), to require that licensees that succeed in bringing certain products toward market submit a plan outlining steps they intend to take to promote patient access to those products. This new IRP policy makes it clear that access, defined broadly to include product affordability, availability, acceptability, and sustainability, is of paramount importance in providing a return on taxpayers' investment in biomedical research. This new policy would apply to patent licenses for the commercialization of drugs, biologics, vaccines, or devices. NIH would also employ a tiered approach, where licenses granted for late-stage inventions that are closer to market launch would include more specific, tailored access-oriented provisions, while licenses granted for early-stage inventions would be more flexible to reflect the higher uncertainty associated with technologies that lead to drugs, biologics, vaccines, or devices. Importantly, a final policy approach should be reasonable and not seek to force licensees into access obligations that obstruct commercial development or damage the viability and sustainability of a product in the market, while also balancing the need to promote access through reforms to various policies. The agency is proposing a flexible approach that allows appropriately tailored, commercially reasonable strategies to promote patient access across a range of technologies. This RFI is in relation to the licensing of government-owned inventions in accordance with 35 U.S.C. 207 and 37 CFR part 404....

Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.

ICH *Varying deadlines depending on regulatory authority*

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Guideline Draft:

https://database.ich.org/sites/default/files/ICH_M14_Step3_DraftGuideline_2024_0521.pdf

Public consultation dates [announced to date]:

MFDS, Republic of Korea - Deadline for comments by 15 July 2024

MHLW/PMDA, Japan - Deadline for comments by 28 July 2024

TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *